Decompensation of Cardiac Hypertrophy: Cellular Mechanisms and Novel Therapeutic Targets
- 1 February 2007
- journal article
- review article
- Published by American Physiological Society in Physiology
- Vol. 22 (1), 56-64
- https://doi.org/10.1152/physiol.00033.2006
Abstract
Cardiac hypertrophy leads to heart failure, and both conditions can ultimately prove lethal. Here, traditional and novel mechanisms relating hypertrophy and heart failure are described at the physiological, cellular, and molecular levels. The rational application of these mechanistic considerations to therapeutics targeting hypertrophy and heart failure is discussed.Keywords
This publication has 80 references indexed in Scilit:
- Control of Cardiac Growth by Histone Acetylation/DeacetylationCirculation Research, 2006
- The Mitochondrial Death Pathway and Cardiac Myocyte ApoptosisCirculation Research, 2004
- Diphtheria Toxin-induced Autophagic Cardiomyocyte Death Plays a Pathogenic Role in Mouse Model of Heart FailureOnline Journal of Public Health Informatics, 2004
- Concentric versus eccentric remodelingJournal of Cardiac Failure, 2002
- Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivoProceedings of the National Academy of Sciences of the United States of America, 2002
- Divergent transcriptional responses to independent genetic causes of cardiac hypertrophyPhysiological Genomics, 2001
- The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic miceThe EMBO Journal, 2000
- The Bcl-2 Protein Family: Arbiters of Cell SurvivalScience, 1998
- Enhanced Gαq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failureProceedings of the National Academy of Sciences of the United States of America, 1998
- The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failureJournal of Molecular and Cellular Cardiology, 1995